Table III.

Doubling times, fold-increase at 96 hours and predicted survival fraction for cytostatic agents (Predicted Ymin).

Cell Line	Doubling time (h)	Fold-Increase at 96 Hrs	Predicted Ymin (%)*	Observed Ymin (%)				Modeled Ymin (%)**
				VCR	LPAM	ETO	RM	VCR	LPAM	ETO	RM
RD	23	18.3	5.5	10.7	4.6	4.0	71.2	10.0	12.3	16.1	63.0
Rh41	44	4.5	22.2	6.0	0.3	0.7	27.4	5.7	1.0	3.0	28.6
Rh18	83	2.2	44.6	64.9	6.8	23.6	76.6	67.2	0.0	0.0	80.6
Rh30	37	6	16.6	18.8	0.8	1.2	42.2	23.1	2.0	2.2	42.7
BT-12	27	12.1	8.2	5.9	0.5	2.2	60.8	8.1	1.0	2.6	60.2
SJ-GBM2	29	10.1	9.9	9.3	0.6	0.4	49.6	6.3	1.2	1.2	50.7
CHLA-266	50	3.8	26.1	29.7	10.1	1.1	60.0	27.7	10.7	0.0	60.3
CHLA-9	20	27.4	3.6	0.4	0.0	0.1	47.6	0.4	4.9	0.6	50.4
CHLA-10	24	15.9	6.3	1.4	2.4	0.6	25.4	1.3	1.9	1.0	26.3
CHLA-258	71	2.6	39	11.2	6.0	6.8	47.4	2.7	2.9	15.1	51.4
TC-71	15	77.4	1.3	0.0	0.1	0.1	75.4	2.4	0.0	3.0	79.7
NB-1643	43	4.7	21.1	7.6	2.3	1.1	59.3	6.9	0.2	0.1	61.1
NB-Ebc1	45	4.4	22.8	26.9	0.5	0.5	64.2	0.0	0.7	0.4	65.9
CHLA-90	52	3.6	27.9	10.8	19.6	6.6	41.7	10.8	23.8	10.1	43.0
CHLA-136	53	3.5	28.7	41.5	7.9	3.9	76.8	1.5	6.2	3.2	75.9
NALM-6	19	34.5	2.9	0.1	0.0	0.0	69.1	0.1	0.0	0.2	72.0
COG-LL-317	21	22.4	4.5	0.1	0.0	0.0	23.5	0.1	0.0	0.0	23.4
RS4;11	35	6.6	15.1	0.1	0.0	0.0	73.2	12.4	1.2	0.0	77.0
MOLT-4	29	10	10	0.0	0.0	0.0	27.0	0.0	0.0	0.6	28.5
CEM	24	15.9	6.3	1.2	0.1	0.0	23.6	0.0	0.9	0.2	23.8
Kasumi-1	53	3.5	28.7	2.1	0.2	0.2	49.3	1.3	0.0	2.6	51.1
Karpas-299	26	12.9	7.8	0.7	0.0	0.0	26.5	2.2	1.1	3.1	23.6
Ramos-RA1	14	105.2	1	0.0	0.1	0.0	14.4	1.9	0.9	1.3	14.7

LPAM: melphalan;

^*The survival fraction calculated for each cell line in the case of the drug being cytostatic;

^**In the cases that Modeled Ymin (minimal survival fraction at the highest concentration tested) estimated using Kaleidagraph is less than 0, we used 0.001 to determine Relative I/O for Fig. 4